Utility of napsin a and thyroid transcription factor 1 in differentiating metastatic pulmonary from non-pulmonary adenocarcinoma in pleural effusion

Acta Cytologica

Volumn 55, Issue 3, 2011, Pages 266-270

  Kim, Jo Heon ^a   Kim, Young Sill ^a   Choi, Yoo Duk ^b   Lee, Ji Shin ^b   Park, Chang Soo ^b  

^a Jeju National University School of Medicine   (South Korea)

^b Chonnam National University Medical School   (South Korea)

Author keywords

Adenocarcinoma; Cell block; Effusion; Immunohistochemistry; Lung; Napsin A; Thyroid transcription factor 1

Indexed keywords

ASPARTIC PROTEINASE; PROTEIN NAPSIN A; THYROID TRANSCRIPTION FACTOR 1; UNCLASSIFIED DRUG; NAPSA PROTEIN, HUMAN; NUCLEAR PROTEIN; THYROID NUCLEAR FACTOR 1; TRANSCRIPTION FACTOR; TUMOR MARKER;

ARTICLE; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; METASTASIS; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADENOCARCINOMA; LUNG TUMOR; METABOLISM; PATHOLOGY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ASPARTIC ACID ENDOPEPTIDASES; DIAGNOSIS, DIFFERENTIAL; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; NUCLEAR PROTEINS; PLEURAL EFFUSION, MALIGNANT; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 79960894792     PISSN: 00015547     EISSN: 19382650     Source Type: Journal    
DOI: 10.1159/000326954     Document Type: Article

References (13)

1. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, Ward E, Wu XC, Eheman C, Anderson R, Ajani UA, Kohler B, Edwards BK: Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008; 100: 1672-1694.
2. Koss LG: Koss' Diagnostic Cytology and Its Histopathological Bases, ed 5. Philadelphia, Lippincott Williams & Wilkins, 2006, pp 949-1022.
3. Fang F, Yang L, Su XL, He Q, Liu DG, Lin FR, Ma ZZ: Determining the primary site of metastatic adenocarcinoma in serous fluid: a cytological study. Zhonghua Bing Li Xue Za Zhi 2005; 34: 641-645.
4. Jagirdar J: Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Lab Med 2008; 132: 384-396.
5. Bishop JA, Sharma R, Illei PB: Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol 2010; 41: 20-25.
6. Ng WK, Chow JC, Ng PK: Thyroid transcription factor-1 is highly sensitive and specific in differentiating metastatic pulmonary from extrapulmonary adenocarcinoma in effusion fluid cytology specimens. Cancer 2002; 96: 43-48.
7. Gomez-Fernandez C, Jorda M, Delgado PI, Ganjei-Azar P: Thyroid transcription factor 1: a marker for lung adenocarcinoma in body cavity fluids. Cancer 2002; 96: 289-293.
8. Suzuki A, Shijubo N, Yamada G, Ichimiya S, Satoh M, Abe S, Sato N: Napsin A is useful to distinguish primary lung adenocarcinoma from adenocarcinomas of other organs. Pathol Res Pract 2005; 201: 579-586.
9. Yang M, Nonaka D: A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol 2010; 23: 654-661.
10. Dejmek A, Naucler P, Smedjeback A, Kato H, Maeda M, Yashima K, Maeda J, Hirano T: Napsin A (TA02) is a useful alternative to thyroid transcription factor-1 (TTF-1) for the identification of pulmonary adenocarcinoma cells in pleural effusions. Diagn Cytopathol 2007; 35: 493-497.
11. Stoll LM, Johnson MW, Gabrielson E, Askin F, Clark DP, Li QK: The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas. Cancer Cytopathol 2010; 118: 441-449.
12. Kim JH, Kim GE, Choi YD, Lee JS, Lee JH, Nam JH, Choi C: Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks. Diagn Cytopathol 2009; 37: 258-261.
13. Ueno T, Linder S, Elmberger G: Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. Br J Cancer 2003; 88: 1229-1233.